Wiviott Stephen D, Morrow David A, Frederick Paul D, Giugliano Robert P, Gibson C Michael, McCabe Carolyn H, Cannon Christopher P, Antman Elliott M, Braunwald Eugene
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
J Am Coll Cardiol. 2004 Aug 18;44(4):783-9. doi: 10.1016/j.jacc.2004.05.045.
We sought to evaluate a simple risk index based on age and vital signs in a community sample of patients with ST-segment elevation myocardial infarction (STEMI).
A simple risk index based on age and vital signs (heart rate x age/10/systolic blood pressure) developed from patients with STEMI accurately predicts mortality in clinical trials of fibrinolysis. The application of such a tool in an unselected population is necessary to evaluate its utility in clinical practice.
To evaluate the Thrombolysis In Myocardial Infarction (TIMI) risk index for routine practice, we tested it in the National Registry of Myocardial Infarction (NRMI)-3 and -4. The risk index was evaluated as a continuous variable in patients with STEMI from NRMI and in subgroups based on age and reperfusion status.
A total of 153,486 patients with STEMI were eligible. As anticipated, STEMI patients in NRMI had a higher risk index profile, as compared with those in the clinical trial (median 26.9 vs. 20, p < 0.0001). Classification of NRMI patients with STEMI into risk groups revealed a significant graded relationship with mortality (0.9% to53.2%, p(trend) < 0.0001, c statistic 0.79). The discriminatory capacity of the risk index was particularly strong in the 81,679 patients receiving reperfusion therapy (0.6% to60%, p(trend) < 0.0001, c statistic 0.81). For the 71,807 patients not receiving reperfusion therapy, a strong graded relationship remained (1.9% to 52.2%, p(trend) < 0.0001, c statistic 0.71). Among the elderly, although the distribution of scores was shifted toward higher risk, the performance remained (0% to 53.1%, p(trend)< 0.0001, c statistic 0.71).
A simple risk index from baseline clinical variables routinely obtained at the first patient encounter predicted mortality in a large unselected heterogeneous group of patients with STEMI.
我们试图在社区样本的ST段抬高型心肌梗死(STEMI)患者中评估一种基于年龄和生命体征的简单风险指数。
从STEMI患者中得出的一种基于年龄和生命体征(心率×[年龄/10]²/收缩压)的简单风险指数在纤维蛋白溶解的临床试验中能准确预测死亡率。有必要在未经过挑选的人群中应用这样一种工具来评估其在临床实践中的效用。
为了评估心肌梗死溶栓(TIMI)风险指数在常规实践中的情况,我们在国家心肌梗死注册库(NRMI)-3和-4中对其进行了测试。该风险指数在来自NRMI的STEMI患者以及基于年龄和再灌注状态的亚组中作为连续变量进行评估。
共有153486例STEMI患者符合条件。正如预期的那样,与临床试验中的患者相比,NRMI中的STEMI患者有更高的风险指数特征(中位数26.9对20,p<0.0001)。将NRMI中的STEMI患者分类为风险组显示出与死亡率有显著的分级关系(0.9%至53.2%,p趋势<0.0001,c统计量0.79)。在接受再灌注治疗的81679例患者中,风险指数的鉴别能力尤为强大(0.6%至60%,p趋势<0.0001,c统计量0.81)。对于71807例未接受再灌注治疗的患者,仍然存在强烈的分级关系(1.9%至52.2%,p趋势<0.0001,c统计量0.71)。在老年人中,尽管评分分布向更高风险偏移,但其性能仍然良好(0%至53.1%,p趋势<0.0001,c统计量0.71)。
在首次接诊患者时常规获取的基线临床变量得出的简单风险指数能预测一大群未经挑选的异质性STEMI患者的死亡率。